Autophagy during cardiac remodeling

Journal of Molecular and Cellular Cardiology

Volumn 95, Issue , 2016, Pages 11-18

  Nishida, Kazuhiko ^a   Otsu, Kinya ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autophagy; Cardiac hypertrophy; Cardiac remodeling; Heart failure; Inflammation; Reverse remodeling

Indexed keywords

ADENYLATE KINASE; LOSARTAN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 9;

ADAPTATION; AUTOPHAGY; BLOOD PRESSURE REGULATION; CARDIAC MUSCLE CELL; CARDIAC REMODELING; CELL DEATH; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; EXERCISE; HEART DILATATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE DILATATION; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; INDUSTRIALIZATION; MITOCHONDRIAL BIOGENESIS; MITOPHAGY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; DISEASE COURSE; HEART; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HEMODYNAMICS; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AUTOPHAGY; CARDIOMEGALY; DISEASE PROGRESSION; HEART; HEART FAILURE; HEMODYNAMICS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 84949656709     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.12.003     Document Type: Review

References (98)

1. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013, 128:e240-e327.
2. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 1999, 79:215-262.
3. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
4. Gottlieb R.A., Mentzer R.M. Autophagy: an affair of the heart. Heart Fail. Rev. 2013, 18:575-584.
5. Osterholt M., Nguyen T.D., Schwarzer M., Doenst T. Alterations in mitochondrial function in cardiac hypertrophy and heart failure. Heart Fail. Rev. 2013, 18:645-656.
6. De Boer R.A., Pinto Y.M., Van Veldhuisen D.J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003, 10:113-126.
7. Tarazi R.C., Fouad F.M. Reversal of cardiac hypertrophy by medical treatment. Annu. Rev. Med. 1985, 36:407-414.
8. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
9. Lamb C.A., Yoshimori T., Tooze S.A. The autophagosome: origins unknown, biogenesis complex. Nat. Rev. Mol. Cell Biol. 2013, 14:759-774.
10. Mizushima N., Yoshimori T., Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu. Rev. Cell Dev. Biol. 2011, 27:107-132.
11. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147:728-741.
12. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
13. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
14. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 2007, 13:619-624.
15. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lullmann-Rauch R., et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000, 406:902-906.
16. Nishino I., Fu J., Tanji K., Yamada T., Shimojo S., Koori T., et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (danon disease). Nature 2000, 406:906-910.
17. Nishida Y., Arakawa S., Fujitani K., Yamaguchi H., Mizuta T., Kanaseki T., et al. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009, 461:654-658.
18. Honda S., Arakawa S., Nishida Y., Yamaguchi H., Ishii E., Shimizu S. Ulk1-mediated Atg5-independent macroautophagy mediates elimination of mitochondria from embryonic reticulocytes. Nat. Commun. 2014, 5:4004.
19. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 2006, 7:589-600.
20. Sag C.M., Santos C.X., Shah A.M. Redox regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 2014, 73:103-111.
21. Yamaguchi O., Higuchi Y., Hirotani S., Kashiwase K., Nakayama H., Hikoso S., et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15883-15888.
22. Kannan A., Janardhanan R. Hypertension as a risk factor for heart failure. Curr. Hypertens. Rep. 2014, 16:447.
23. Rassi A.N., Pibarot P., Elmariah S. Left ventricular remodelling in aortic stenosis. Can. J. Cardiol. 2014, 30:1004-1011.
24. Nishida K., Kyoi S., Yamaguchi O., Sadoshima J., Otsu K. The role of autophagy in the heart. Cell Death Differ. 2009, 16:31-38.
25. Dammrich J., Pfeifer U. Cardiac hypertrophy in rats after supravalvular aortic constriction. II. Inhibition of cellular autophagy in hypertrophying cardiomyocytes. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1983, 43:287-307.
26. Dammrich J., Pfeifer U. Cardiac hypertrophy in rats after supravalvular aortic constriction. I. Size and number of cardiomyocytes, endothelial and interstitial cells. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1983, 43:265-286.
27. Pfeifer U., Fohr J., Wilhelm W., Dammrich J. Short-term inhibition of cardiac cellular autophagy by isoproterenol. J. Mol. Cell. Cardiol. 1987, 19:1179-1184.
28. Li Z., Song Y., Liu L., Hou N., An X., Zhan D., et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ. 2015, (in press). 10.1038/cdd.2015.95.
29. Kuzman J.A., O'Connell T.D., Gerdes A.M. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 2007, 148:3477-3484.
30. Ha T., Li Y., Gao X., McMullen J.R., Shioi T., Izumo S., et al. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic. Biol. Med. 2005, 39:1570-1580.
31. Ucar A., Gupta S.K., Fiedler J., Erikci E., Kardasinski M., Batkai S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 2012, 3:1078.
32. Cao D.J., Wang Z.V., Battiprolu P.K., Jiang N., Morales C.R., Kong Y., et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4123-4128.
33. Oyabu J., Yamaguchi O., Hikoso S., Takeda T., Oka T., Murakawa T., et al. Autophagy-mediated degradation is necessary for regression of cardiac hypertrophy during ventricular unloading. Biochem. Biophys. Res. Commun. 2013, 441:787-792.
34. Koitabashi N., Kass D.A. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 2012, 9:147-157.
35. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 2000, 35:569-582.
36. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001, 345:1667-1675.
37. Christakis G.T., Joyner C.D., Morgan C.D., Fremes S.E., Buth K.J., Sever J.Y., et al. Left ventricular mass regression early after aortic valve replacement. Ann. Thorac. Surg. 1996, 62:1084-1089.
38. Zafeiridis A., Jeevanandam V., Houser S.R., Margulies K.B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98:656-662.
39. Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009, 54:1084-1091.
40. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
41. Hariharan N., Ikeda Y., Hong C., Alcendor R.R., Usui S., Gao S., et al. Autophagy plays an essential role in mediating regression of hypertrophy during unloading of the heart. PLoS One 2013, 8.
42. Cao D.J., Jiang N., Blagg A., Johnstone J.L., Gondalia R., Oh M., et al. Mechanical unloading activates FoxO3 to trigger Bnip3-dependent cardiomyocyte atrophy. J. Am. Heart Assoc. 2013, 2.
43. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N. Engl. J. Med. 1990, 322:1561-1566.
44. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002, 105:509-515.
45. Frieler R.A., Mortensen R.M. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 2015, 131:1019-1030.
46. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J. Clin. Invest. 2007, 117:1782-1793.
47. Rifki O.F., Hill J.A. Cardiac autophagy: good with the bad. J. Cardiovasc. Pharmacol. 2012, 60:248-252.
48. Ma X., Liu H., Foyil S.R., Godar R.J., Weinheimer C.J., Hill J.A., et al. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation 2012, 125:3170-3181.
49. Matsunaga K., Saitoh T., Tabata K., Omori H., Satoh T., Kurotori N., et al. Two beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat. Cell Biol. 2009, 11:385-396.
50. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 2011, 89:265-272.
51. Aranguiz-Urroz P., Canales J., Copaja M., Troncoso R., Vicencio J.M., Carrillo C., et al. Beta(2)-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation. Biochim. Biophys. Acta 1812, 2011:23-31.
52. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol. Cell 2010, 40:280-293.
53. Miyata S., Takemura G., Kawase Y., Li Y., Okada H., Maruyama R., et al. Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. Am. J. Pathol. 2006, 168:386-397.
54. Kassiotis C., Ballal K., Wellnitz K., Vela D., Gong M., Salazar R., et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 2009, 120:S191-S197.
55. Danon M.J., Oh S.J., DiMauro S., Manaligod J.R., Eastwood A., Naidu S., et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981, 31:51-57.
56. Cheng Z., Fang Q. Danon disease: focusing on heart. J. Hum. Genet. 2012, 57:407-410.
57. Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat. Genet. 1998, 20:92-95.
58. Tannous P., Zhu H., Johnstone J.L., Shelton J.M., Rajasekaran N.S., Benjamin I.J., et al. Autophagy is an adaptive response in desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9745-9750.
59. Bhuiyan M.S., Pattison J.S., Osinska H., James J., Gulick J., McLendon P.M., et al. Enhanced autophagy ameliorates cardiac proteinopathy. J. Clin. Invest. 2013, 123:5284-5297.
60. Billia F., Hauck L., Konecny F., Rao V., Shen J., Mak T.W. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9572-9577.
61. Kobayashi S., Liang Q. Autophagy and mitophagy in diabetic cardiomyopathy. Biochim. Biophys. Acta 1852, 2015:252-261.
62. Xu X., Kobayashi S., Chen K., Timm D., Volden P., Huang Y., et al. Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J. Biol. Chem. 2013, 288:18077-18092.
63. Abbate A. The heart on fire: inflammasome and cardiomyopathy. Exp. Physiol. 2013, 98:385.
64. Butts B., Gary R.A., Dunbar S.B., Butler J. The importance of NLRP3 inflammasome in heart failure. J. Card. Fail. 2015, 21:586-593.
65. Nakayama H., Otsu K. Translation of hemodynamic stress to sterile inflammation in the heart. Trends Endocrinol. Metab. 2013, 24:546-553.
66. Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T., et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485:251-255.
67. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
68. Matsui Y., Takagi H., Qu X., Abdellatif M., Sakoda H., Asano T., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and beclin 1 in mediating autophagy. Circ. Res. 2007, 100:914-922.
69. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283:10892-10903.
70. Idikio H.A. Postmyocardial infarct remodeling and heart failure: potential contributions from pro- and antiaging factors. Cardiol. Res. Pract. 2011, 2011:836806.
71. Kanamori H., Takemura G., Goto K., Maruyama R., Tsujimoto A., Ogino A., et al. The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovasc. Res. 2011, 91:330-339.
72. Sciarretta S., Volpe M., Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ. Res. 2014, 114:549-564.
73. Buss S.J., Muenz S., Riffel J.H., Malekar P., Hagenmueller M., Weiss C.S., et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2435-2446.
74. Li Q., Xie J., Li R., Shi J., Sun J., Gu R., et al. Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. J. Cell. Mol. Med. 2014, 18:919-928.
75. Schiattarella G.G., Hill J.A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 2015, 131:1435-1447.
76. Dorn G.W. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc. Res. 2009, 81:465-473.
77. Diez J., Querejeta R., Lopez B., Gonzalez A., Larman M., Martinez Ubago J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517.
78. Tarone G., Balligand J.L., Bauersachs J., Clerk A., De Windt L., Heymans S., et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the working group on myocardial function of the European society of cardiology. Eur. J. Heart Fail. 2014, 16:494-508.
79. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
80. Chen H.H., Mekkaoui C., Cho H., Ngoy S., Marinelli B., Waterman P., et al. Fluorescence tomography of rapamycin-induced autophagy and cardioprotection in vivo. Circ. Cardiovasc. Imaging 2013, 6:441-447.
81. Khan S., Salloum F., Das A., Xi L., Vetrovec G.W., Kukreja R.C. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 41:256-264.
82. Bishu K., Ogut O., Kushwaha S., Mohammed S.F., Ohtani T., Xu X., et al. Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade. PLoS One 2013, 8.
83. Xu X., Lu Z., Fassett J., Zhang P., Hu X., Liu X., et al. Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase alpha2. Hypertension 2014, 63:723-728.
84. Gundewar S., Calvert J.W., Jha S., Toedt-Pingel I., Ji S.Y., Nunez D., et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 2009, 104:403-411.
85. Moyzis A.G., Sadoshima J., Gustafsson A.B. Mending a broken heart: the role of mitophagy in cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2015, 308:H183-H192.
86. Yamashita N., Hoshida S., Otsu K., Asahi M., Kuzuya T., Hori M. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J. Exp. Med. 1999, 189:1699-1706.
87. Carreira R.S., Lee P., Gottlieb R.A. Mitochondrial therapeutics for cardioprotection. Curr. Pharm. Des. 2011, 17:2017-2035.
88. Lavie C.J., Arena R., Swift D.L., Johannsen N.M., Sui X., Lee D.C., et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ. Res. 2015, 117:207-219.
89. Mizushima N., Yamamoto A., Matsui M., Yoshimori T., Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 2004, 15:1101-1111.
90. Godar R.J., Ma X., Liu H., Murphy J.T., Weinheimer C.J., Kovacs A., et al. Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy 2015, 11:1537-1560.
91. Seta Y., Shan K., Bozkurt B., Oral H., Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. 1996, 2:243-249.
92. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
93. Hedayat M., Mahmoudi M.J., Rose N.R., Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail. Rev. 2010, 15:543-562.
94. Nishida K., Yamaguchi O., Otsu K. Degradation systems in heart failure. J. Mol. Cell. Cardiol. 2015, 84:212-222.
95. Nishida K., Yamaguchi O., Otsu K. Crosstalk between autophagy and apoptosis in heart disease. Circ. Res. 2008, 103:343-351.
96. Ouyang C., You J., Xie Z. The interplay between autophagy and apoptosis in the diabetic heart. J. Mol. Cell. Cardiol. 2014, 71:71-80.
97. Okamoto K., Kondo-Okamoto N., Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev. Cell 2009, 17:87-97.
98. Murakawa T., Yamaguchi O., Hashimoto A., Hikoso S., Takeda T., Oka T., et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat. Commun. 2015, 6:7527.